Denali Therapeutics Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed February 28, 2022. This is an annual report, not a standalone Q4 report. Denali is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, including blood-brain-barrier transport technologies. It had no approved products and no product sales.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Collaboration revenue | $48.7 million | $335.7 million |
| Research and development expense | $265.4 million | $212.6 million |
| General and administrative expense | $79.1 million | $60.3 million |
| Operating loss | $295.8 million | Operating income of $62.7 million |
| Net income (loss) | $(290.6) million | $71.1 million |
| Operating cash flow | $(211.4) million | $416.2 million |
Revenue fell 86% year over year, chiefly because Denali recognized $307.4 million of Biogen collaboration revenue in 2020 versus $3.7 million in 2021. The 2021 loss reflects lower collaboration revenue and higher operating costs; R&D expense rose 25%, partly offset by increased partner cost reimbursements. Stock-based compensation totaled $85.2 million, up from $50.4 million.
At year-end, cash, cash equivalents and marketable securities totaled approximately $1.291 billion, down from approximately $1.502 billion in 2020. Total assets were $1.404 billion and stockholders’ equity was $962.3 million. Current assets of $897.2 million exceeded current liabilities of $378.2 million. The balance sheet reports no conventional borrowings; it includes $64.0 million of operating lease liabilities. Contract liabilities totaled approximately $324.0 million, including a substantial Biogen-related deferred balance.
There is no meaningful product gross margin because Denali had no product sales. Net loss per share was $2.39, compared with net income per share of $0.65 in 2020. Management said existing cash, cash equivalents and marketable securities were expected to fund projected operations through at least 12 months after filing, subject to assumptions; it anticipates substantial future losses and may need additional capital over time.
Pipeline, developments and outlook
- DNL310 for Hunter syndrome: In the Phase 1/2 trial, company-reported data available in February 2022 showed normalized CSF heparan sulfate in all 20 patients by Week 24, sustained to Week 49 in the five Cohort A patients. Clinical outcome observations were exploratory, and infusion-related reactions were common (15 of 20 patients); one patient had severe reactions. A potentially registrational Phase 2/3 trial was planned to begin dosing in the first half of 2022.
- BIIB122/DNL151 for Parkinson’s disease: Phase 1 and 1b studies showed target and pathway biomarker engagement and were generally well tolerated over treatment of up to 28 days. Two partner-led late-stage studies were expected to begin dosing in 2022; longer-term efficacy and safety remained unestablished.
- DNL343 for ALS: A Phase 1 healthy-volunteer study reported CNS distribution, pathway biomarker effects and generally good short-term tolerability. A Phase 1b ALS study began dosing in 2021, with results expected in mid-2022.
- Partnered RIPK1 programs: Sanofi planned a Phase 2 ALS trial of SAR443820/DNL788 in early 2022; the candidate received FDA Fast Track designation. Sanofi discontinued COVID-19 development of SAR443122/DNL758 but continued development in cutaneous lupus.
- DNL919 for Alzheimer’s disease: After year-end, the FDA placed the IND on clinical hold over preclinical toxicology and requested additional information. Denali expected at least a three-month delay to first dosing; the hold’s resolution was uncertain.
- DNL593 for FTD-GRN: Takeda exercised its option in 2021. The UK trial application was approved in January 2022, triggering a $12 million milestone received in February; healthy-volunteer dosing was expected in Q1 2022.
Denali’s strategy emphasizes genetically supported targets, brain delivery and biomarkers, while advancing programs selectively and partnering on development and commercialization. It reported plans to expand clinical manufacturing capabilities through a Salt Lake City facility. There was no formal financial guidance or projected product revenue; management cautioned that trial timing, costs, regulatory outcomes and financing needs are uncertain.
Risks, contingencies and unusual items
- Clinical and regulatory risk is significant: no candidate had completed pivotal testing or received marketing approval. Biomarker changes and interim clinical observations do not establish clinical benefit.
- Denali depends on collaborators, contract research organizations and external manufacturers. Partner decisions, cost-sharing obligations, manufacturing capacity and trial execution could affect program timing and economics.
- COVID-19 had previously disrupted trial recruitment and laboratory efficiency; further effects on trials, suppliers and operations remained possible.
- Cash and investment balances are substantial, but ongoing operating losses and development spending may require additional financing. Equity financing could dilute shareholders; debt or partnerships could impose restrictions or reduce future economics.
- Year-end marketable securities had $2.1 million of gross unrealized losses; the company reported no credit-loss allowance and said it intended and was able to hold the securities to maturity or recovery.
- Lease liabilities were $64.0 million; additional disclosed commitments included $28.3 million under the Lonza manufacturing agreement, $11.5 million under other development/manufacturing agreements, and $8.0 million for Utah facility equipment. Certain commitments are subject to partner cost sharing.
- A shareholder derivative action concerning director compensation was settled in 2021; the company said its payments were not material. Management reported effective disclosure controls and internal control over financial reporting, and the auditor issued unqualified opinions on the financial statements and internal controls.
Investor facts to verify
- Whether DNL310’s planned Phase 2/3 trial began as expected, and whether clinical outcomes—not only biomarkers—support meaningful benefit and an acceptable safety profile.
- Resolution and timing of the DNL919 clinical hold, including any changes to the toxicology package or proposed trial.
- Initiation, enrollment, duration and eventual efficacy and safety results for BIIB122/DNL151, DNL343 and Sanofi-led trials.
- Cash burn, collaboration receipts and cost-sharing balances relative to the stated runway; also monitor deferred collaboration revenue and commitments.
- How partner option exercises, cost-sharing requirements and future milestones affect Denali’s retained economics and development spending.